[Using deltalicin for the treatment of patients with diabetic retinopathy].
The characteristics of visual evoked potential (VEP) have been investigated in a group of 15 healthy volunteers (aged 31.7 ± 3.6 years) and 30 insulin-dependent patients (aged 32.1 ± 4.0 years) with diabetes mellitus, among which 15 patients suffered from diabetic retinopathy and 15 patients had no retinopathy. An increase in the latent period along with reduction of the VEP amplitude after photostress action upon the macular part of retina have been observed in patients with diabetes, these effects were more pronounced in the subgroup with retinopathy. The restoration of VEP characteristics in 73.5 ± 3.3 s from the moment of photostress was observed in the control group, while this index in both subgroups of diabetic patients without and with retinopathy was 88.7 ± 5.9 and 137.2 ± 11.3 s, respectively. Treatment with deltalicin (daily dose of 0.0003 g of delta sleep-inducing peptide intranasally for two months) decreased the latent period and led to less pronounced depression of VEP amplitude in patients with diabetic retinopathy, and reduced the period of restoration of VEP characteristics to 95.1 ± 6.8 s.
N V
NV
Kresiun
L S
LS
Godlevskiĭ
D000328:Adult; D003701:Delta Sleep-Inducing Peptide / Q000008:administration & dosage / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology; D005074:Evoked Potentials, Visual / Q000187:drug effects; D006801:Humans; D018377:Neurotransmitter Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010775:Photic Stimulation; D016896:Treatment Outcome
D018377:Neurotransmitter Agents; D003701:Delta Sleep-Inducing Peptide